Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria.
Corrado D, Perazzolo Marra M, Zorzi A, Beffagna G, Cipriani A, Lazzari M, Migliore F, Pilichou K, Rampazzo A, Rigato I, Rizzo S, Thiene G, Anastasakis A, Asimaki A, Bucciarelli-Ducci C, Haugaa KH, Marchlinski FE, Mazzanti A, McKenna WJ, Pantazis A, Pelliccia A, Schmied C, Sharma S, Wichter T, Bauce B, Basso C.
Int J Cardiol. 2020 Nov 15;319:106-114. doi: 10.1016/j.ijcard.2020.06.005. Epub 2020 Jun 16.
PMID:32561223
The Role of Contrast-Enhanced Cardiac Magnetic Resonance in the Assessment of Patients with Malignant Ventricular Arrhythmias.
Banerji D, Mendoza D, Ghoshhajra BB, Hedgire SS.
Magn Reson Imaging Clin N Am. 2019 Aug;27(3):475-490. doi: 10.1016/j.mric.2019.04.011.
PMID:31279451
Efficacy of moricizine in malignant ventricular arrhythmias.
Horowitz LN.
Am J Cardiol. 1990 Feb 20;65(8):41D-46D; discussion 68D-71D. doi: 10.1016/0002-9149(90)91416-4.
PMID:1689535
Patients with malignant or potentially malignant ventricular arrhythmias: opportunities and limitations of drug therapy in prevention of sudden death.
Bigger JT Jr.
J Am Coll Cardiol. 1985 Jun;5(6 Suppl):23B-26B. doi: 10.1016/s0735-1097(85)80521-0.
PMID:3889110
Electrocardiographic recognition of benign and malignant right ventricular arrhythmias.
Lee J, Adeola O, Garan H, Stevenson WG, Yarmohammadi H.